Back to School: How biopharma can reboot drug development. Access exclusive analysis here

G-BA issues three benefit assessments

Germany's Federal Joint Committee (G-BA) issued final assessments for three drugs on Thursday. G-BA said Xalkori crizotinib from Pfizer Inc. (NYSE:PFE) has "significant" additional benefit over docetaxel or pemetrexed-containing chemotherapy in patients with previously treated, advanced non-small cell

Read the full 386 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE